Why subscribe?

Subscribe to get full access to the newsletter and website. Never miss an update. $IPA

Stay up-to-date

You won’t have to worry about missing anything. Every new edition of the newsletter goes directly to your inbox.

Join the crew

Be part of a IPA’s community of people who share your interests.

To find out more about the company that provides the tech for this newsletter, visit Substack.com.

Forward Looking Information 

 
This blog  contains forward-looking statements within the meaning of applicable United States securities laws and Canadian securities laws. Forward-looking statements are often identified by the use of words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking information contained in this blog include, but are not limited to, statements regarding the potential of PolyTope® TATX-03 to retain efficacy against COVID-19 disease or any variant of the virus, to have synergistic effects, to require smaller doses and with the timing and plans for submission of an Investigational New Drug filing and commencement of a Phase I clinical trial of TATX-03. In respect of the forward-looking information contained herein, ImmunoPrecise has provided such statements and information in reliance on certain assumptions that ImmunoPrecise believed to be reasonable at the time. 

Forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. Actual results could differ materially from those currently anticipated due to a number of factors and risks, including, without limitation, ImmunoPrecise may not be successful in timely developing its PolyTope® monoclonal antibodies, including TATX-03, or other vaccines or therapeutics against COVID-19 or may not receive all regulatory approvals to commence and then continue clinical trials of its products, including PolyTope® TATX-03 and, be successful in partnering or commercializing its products related to COVID-19, the coverage and applicability of the ImmunoPrecise’s intellectual property rights to its PolyTope® antibody cocktails, as well as those risks discussed in the Company’s Annual Information Form dated July 27, 2021 (which may be viewed on the Company’s profile at www.sedar.com) and the Company’s Form 40-F, Amendment No, 1 dated September 28, 2021 (which may be viewed on the Company’s profile at www.sec.gov).  Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this blog Accordingly, readers should not place undue reliance on forward-looking information contained in this blog. 

The forward-looking statements contained in this blog are made as of the date of this release and, accordingly, are subject to change after such date. The Company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law. 

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the information in this blog. 

SOURCE ImmunoPrecise Antibodies 

Subscribe to IPA’s Newsletter

ImmunoPrecise haiku / To discover and bring alive / mAbs, therapies

People

IPA is a biotherapeutic, innovation-powered company that supports its business partners in their quest to discover and develop novel antibodies against a broad range of target classes and diseases.